A Phase 2 interventional study of CB-03-01 and Vehicle in Acne Vulgaris, sponsored by Intrepid Therapeutics, Inc.. Completed at 13 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2020-11-16.
Sponsored by Intrepid Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing clascoterone in Acne Vulgaris — 5 open to participants now, 7 under way, 2 of them phase 3. Clascoterone · Acne Vulgaris.
Among the 19 studies testing clascoterone in Acne Vulgaris, this one is the 6th largest by enrollment, is the only one that started in 2012, is one of 3 in phase 2, and was the 1st registered.
791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.
Browse Acne Vulgaris studies →5 of the 19 studies testing clascoterone in Acne Vulgaris are open now, in 2 countries. Recruiting first, the newest first:
Pak Emirates Military Hospital · Sites in Pakistan
Ages 12–55
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. · Sites in China
Ages 12+
Allied Hospital Faisalabad · Sites in Pakistan
Ages 15+
Khyber Teaching Hospital
Ages 12–35
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.
Ages 12+
By country, each count listing its studies:
Clascoterone: first FDA approval 2020 (WINLEVI), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →
Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 5 · Phase 4 7
First in 2012; this study’s year is marked. 1 started in 2012.
This study's enrollment of 363 is above the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 50 across the 19 interventional studies. Of the 12 that completed or were terminated, 11 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 19 have an industry lead sponsor. The 8 most frequent:
Intrepid Therapeutics, Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.
Intrepid Therapeutics, Inc. has 2 studies filed under Acne Vulgaris — fewer than ten, so there is no comparison to draw.
3 of the studies testing clascoterone in Acne Vulgaris that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07673094Khyber Teaching HospitalComparison of Topical Clascoterone and Adapalene for Mild Acne Vulgaris | 2027-02 |
| NCT07883538Pak Emirates Military HospitalComparison of Topical Clascoterone 1% Cream Versus Adapalene 0.1% Cream in the Treatment of Mild-to-Moderate Acne Vulgaris | 2027-04-30 |
| NCT07881315Allied Hospital FaisalabadClascoterone Versus Clindamycin Added to Adapalene/Benzoyl Peroxide for Moderate Facial Acne | 2027-05 |
Add all 3 to your calendar (.ics) → With an account.
Among the 19 studies testing clascoterone in Acne Vulgaris, from their registry updates:
This tab as a report to print or save as PDF → With an account.
CB-03-01 is being developed for the topical treatment of acne vulgaris, an androgen-dependent skin disorder. The purpose of this study is to compare the safety and efficacy of multiple concentrations of CB-03-01 to vehicle in the treatment of acne vulgaris.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subject has used any of the following topical anti-acne preparations or procedures on the face:
Subject has used the following systemic anti-acne medications:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
low dose of CB-03-01, 0.1% applied twice a day
Drug: CB-03-01
medium dose of CB-03-01, 0.5% applied twice a day
Drug: CB-03-01
high dose of CB-03-01, 1% applied once a day
Drug: CB-03-01
high dose of CB-03-01, 1% applied twice a day
Drug: CB-03-01
vehicle cream, applied once or twice a day
Drug: Vehicle
Investigator's Global Assessment (IGA) "Success" - Week 12
Count and percentage of subjects achieving success in each treatment group at Week 12 using the dichotomized IGA with success defined as a score of "clear" or "almost clear" (IGA Score of 0 or 1) and a two or more grade improvement from Baseline using a five-point scale (0=clear to 4=severe).
Time frame: Baseline and Week 12
Inflammatory and Non-Inflammatory Lesion Counts - Week 12
Absolute change from Baseline in inflammatory and non-inflammatory lesion counts in each treatment group at Week 12.
Time frame: Baseline and Week 12
Inflammatory and Non-Inflammatory Lesion Counts - Week 8
Absolute change from Baseline in inflammatory and non-inflammatory lesion counts in each treatment group at Week 8.
Time frame: Baseline and Week 8
Percent Change in Lesion Counts - Weeks 8 and 12
Percent change from Baseline in lesion counts (inflammatory and noninflammatory) in each treatment group at Weeks 8 and 12.
Time frame: Week 8 and Week 12
IGA "Success" - Week 8
Count and percentage of subjects achieving success per the IGA in each treatment group at Week 8 ("success" as defined in the primary endpoints section).
Time frame: Baseline and Week 8
IGA "Clear" or "Almost Clear" - Weeks 4, 8 and 12
Count and percentage of subjects who are "clear" or "almost clear" (IGA Grade 0 or 1) in each treatment group at Weeks 4, 8 and 12.
Time frame: Weeks 4, 8, and 12
| Milestone | Low-dose Active, BID | Medium-dose Active, BID | High-dose Active, QD | High-dose Active, BID | Vehicle, QD or BID |
|---|---|---|---|---|---|
| Started | 72 | 76 | 70 | 70 | 75 |
| Completed | 58 | 64 | 61 | 59 | 62 |
| Not completed | 14 | 12 | 9 | 11 | 13 |
| Withdrew: Lost to follow-up | 8 | 5 | 7 | 5 | 5 |
| Withdrew: Withdrawal by subject | 4 | 4 | 2 | 6 | 5 |
| Withdrew: Lack of efficacy | 2 | 2 | 0 | 0 | 2 |
| Withdrew: Noncompliance with study drug | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 |
Count and percentage of subjects achieving success in each treatment group at Week 12 using the dichotomized IGA with success defined as a score of "clear" or "almost clear" (IGA Score of 0 or 1) and a two or more grade improvement from Baseline using a five-point scale (0=clear to 4=severe).
| Participants | Low-dose Active, BID | Medium-dose Active, BID | High-dose Active, QD | High-dose Active, BID | Vehicle, QD or BID |
|---|---|---|---|---|---|
| Investigator's Global Assessment (IGA) "Success" - Week 12 | 5 | 3 | 2 | 6 | 2 |
Absolute change from Baseline in inflammatory and non-inflammatory lesion counts in each treatment group at Week 12.
| lesions | Low-dose Active, BID | Medium-dose Active, BID | High-dose Active, QD | High-dose Active, BID | Vehicle, QD or BID |
|---|---|---|---|---|---|
| Inflammatory lesions | -8.3 ± 14.63 | -5.8 ± 11.99 | -10.1 ± 12.53 | -12.3 ± 14.43 | -9.1 ± 13.67 |
| Non-inflammatory lesions | -8.7 ± 18.16 | -6.1 ± 29.22 | -8.4 ± 21.55 | -15.5 ± 20.48 | -6.7 ± 19.65 |
Absolute change from Baseline in inflammatory and non-inflammatory lesion counts in each treatment group at Week 8.
| lesions | Low-dose Active, BID | Medium-dose Active, BID | High-dose Active, QD | High-dose Active, BID | Vehicle, QD or BID |
|---|---|---|---|---|---|
| Inflammatory lesions | -11.9 ± 8.84 | -7.2 ± 12.03 | -7.2 ± 17.21 | -11.5 ± 11.19 | -11.3 ± 12.71 |
| Non-inflammatory lesions | -7.0 ± 13.76 | -6.7 ± 16.33 | -3.2 ± 37.01 | -13.6 ± 17.99 | -8.3 ± 17.12 |
Percent change from Baseline in lesion counts (inflammatory and noninflammatory) in each treatment group at Weeks 8 and 12.
| percentage of change | Low-dose Active, BID | Medium-dose Active, BID | High-dose Active, QD | High-dose Active, BID | Vehicle, QD or BID |
|---|---|---|---|---|---|
| Inflammatory lesions (Week 8) | -40.6 ± 28.20 | -26.6 ± 37.35 | -27.5 ± 41.44 | -41.1 ± 36.54 | -36.0 ± 35.01 |
| Inflammatory lesions (Week 12) | -26.8 ± 50.78 | -21.3 ± 45.33 | -32.5 ± 35.51 | -41.8 ± 52.25 | -28.4 ± 41.88 |
| Non-inflammatory lesions (Week 8) | -18.3 ± 34.50 | -19.5 ± 36.49 | -10.5 ± 57.13 | -33.5 ± 39.26 | -24.3 ± 43.23 |
| Non-inflammatory lesions (Week 12) | -24.3 ± 38.69 | -16.9 ± 55.66 | -19.5 ± 40.75 | -34.1 ± 46.95 | -19.5 ± 47.43 |
Count and percentage of subjects achieving success per the IGA in each treatment group at Week 8 ("success" as defined in the primary endpoints section).
| Participants | Low-dose Active, BID | Medium-dose Active, BID | High-dose Active, QD | High-dose Active, BID | Vehicle, QD or BID |
|---|---|---|---|---|---|
| IGA "Success" - Week 8 | 1 | 3 | 1 | 4 | 2 |
Count and percentage of subjects who are "clear" or "almost clear" (IGA Grade 0 or 1) in each treatment group at Weeks 4, 8 and 12.
| Participants | Low-dose Active, BID | Medium-dose Active, BID | High-dose Active, QD | High-dose Active, BID | Vehicle, QD or BID |
|---|---|---|---|---|---|
| Week 4 | 3 | 1 | 5 | 7 | 2 |
| Week 8 | 3 | 4 | 2 | 6 | 4 |
| Week 12 | 6 | 4 | 3 | 9 | 4 |
Collected over Adverse events (AEs) were collected from screening visit, Baseline (Day 1) and up to Week 12/early termination.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Low-dose Active, BID | 0/72 (0%) | 0/72 (0%) | 12/72 (16.7%) |
| Medium-dose Active, BID | 0/76 (0%) | 0/76 (0%) | 18/76 (23.7%) |
| High-dose Active, QD | 0/70 (0%) | 0/70 (0%) | 9/70 (12.9%) |
| High-dose Active, BID | 0/70 (0%) | 0/70 (0%) | 5/70 (7.1%) |
| Vehicle, QD or BID | 0/75 (0%) | 0/75 (0%) | 5/75 (6.7%) |
| Event | Low-dose Active, BID | Medium-dose Active, BID | High-dose Active, QD | High-dose Active, BID | Vehicle, QD or BID |
|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 6/72 | 8/76 | 2/70 | 3/70 | 2/75 |
| NasopharyngitisInfections and infestations | 1/72 | 0/76 | 4/70 | 1/70 | 0/75 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 1/72 | 4/76 | 1/70 | 0/70 | 0/75 |
| PyrexiaGeneral disorders | 0/72 | 2/76 | 2/70 | 0/70 | 0/75 |
| HeadacheNervous system disorders | 2/72 | 1/76 | 0/70 | 0/70 | 2/75 |
| LacerationInjury, poisoning and procedural complications | 2/72 | 1/76 | 0/70 | 0/70 | 0/75 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 0/72 | 2/76 | 0/70 | 1/70 | 1/75 |
ITT Population. The ITT population included all subjects enrolled in the study who were randomized and dispensed test article.
| Age, Continuous(years) | Low-dose Active, BID | Medium-dose Active, BID | High-dose Active, QD | High-dose Active, BID | Vehicle, QD or BID | Total |
|---|---|---|---|---|---|---|
| Mean | 19.8 ± 5.77 | 20.4 ± 6.31 | 18.3 ± 6.14 | 21.0 ± 6.22 | 19.2 ± 5.25 | 19.7 ± 5.99 |
| Sex: Female, Male(Participants) | Low-dose Active, BID | Medium-dose Active, BID | High-dose Active, QD | High-dose Active, BID | Vehicle, QD or BID | Total |
|---|---|---|---|---|---|---|
| Female | 36 | 42 | 38 | 37 | 43 | 196 |
| Male | 36 | 34 | 32 | 33 | 32 | 167 |
| Ethnicity (NIH/OMB)(Participants) | Low-dose Active, BID | Medium-dose Active, BID | High-dose Active, QD | High-dose Active, BID | Vehicle, QD or BID | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 22 | 20 | 6 | 15 | 13 | 76 |
| Not Hispanic or Latino | 50 | 56 | 64 | 55 | 62 | 287 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Low-dose Active, BID | Medium-dose Active, BID | High-dose Active, QD | High-dose Active, BID | Vehicle, QD or BID | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 2 | 0 | 3 |
| Asian | 1 | 3 | 4 | 4 | 4 | 16 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 0 | 1 | 2 |
| Black or African American | 12 | 14 | 16 | 20 | 12 | 74 |
| White | 58 | 54 | 50 | 42 | 53 | 257 |
| More than one race | 1 | 2 | 0 | 2 | 4 | 9 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 1 | 2 |
| Baseline IGA(Participants) | Low-dose Active, BID | Medium-dose Active, BID | High-dose Active, QD | High-dose Active, BID | Vehicle, QD or BID | Total |
|---|---|---|---|---|---|---|
| 0 - Clear | 0 | 0 | 0 | 0 | 0 | 0 |
| 1 - Almost clear | 0 | 0 | 0 | 0 | 0 | 0 |
| 2 - Mild | 10 | 6 | 15 | 18 | 11 | 60 |
| 3 - Moderate | 56 | 62 | 44 | 32 | 53 | 247 |
| 4 - Severe | 6 | 8 | 11 | 20 | 11 | 56 |
| Baseline lesions counts(lesions) | Low-dose Active, BID | Medium-dose Active, BID | High-dose Active, QD | High-dose Active, BID | Vehicle, QD or BID | Total |
|---|---|---|---|---|---|---|
| Inflammatory lesions | 29.9 (20 to 74) | 29.0 (20 to 74) | 31.9 (20 to 72) | 28.6 (20 to 63) | 30.5 (20 to 75) | 30.0 (20 to 75) |
| Non-inflammatory lesions | 43.5 (21 to 99) | 44.5 (21 to 98) | 46.7 (21 to 91) | 47.2 (20 to 98) | 43.9 (20 to 99) | 45.2 (20 to 99) |
The record gives a start of Jun 2012, a primary completion of Feb 2014 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2020, 6 years 9 months after primary completion. A results delay was requested in Mar 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Clascoterone
Intrepid Therapeutics, Inc.